The pharma industry is no stranger to standards. Pharmaceutical companies have entire teams devoted to ensuring that all data and content is collected, created, managed, retained, and retired according to regulatory requirements.
Vigilante content is all the content created (and often distributed) by people who are not tasked with creating content. It’s the content that someone thinks up and then writes. And then publishes or emails or prints to hand out at a conference. In essence, it is unauthorized content.
Using component-based structured content authoring and having a robust reuse strategy is the only way to produce pharma content at scale. It’s how you produce accurate content efficiently across the enterprise. It’s how you deliver the right content to the right place at the right time, such as when you
We can no longer afford the costs of traditional, document-based content management in the pharmaceutical industry. We need pharma companies to prioritize content reuse and automation rather than manual, error-prone legacy processes.
In January 2022, I received my Year in Review video from WW (formerly Weight Watchers). The video showed me some fun stats about my participation in the program in 2021.
In The Unique Challenges of Pharma Content, we discuss challenges faced by pharmaceutical companies in the creation and management of content.
Most content challenges are ubiquitous, present in every vertical. Processes that don’t scale. Too much content to manage and yet the exact right content never seems to be at hand. Authors must copy and paste and (inevitably) tweak content, wasting time and increasing risk. The challenges of time, cost, and
For centuries, humans have shared information through documents. We’ve used digital files, printed paper, illuminated manuscripts, parchment scrolls, and clay tablets. Regardless of form factor, a document has traditionally been created as a single monolithic entity, authored in the same format in which it was intended to be consumed.
The COVID-19 pandemic put tremendous pressure on drug-development organizations to accelerate product development far beyond anyone’s wildest roadmaps.
Recently, I was working through some challenges with a custom schema that supports the structured content model for one of my pharma customers. I needed to take an existing document and lay it out with both the old schema and the new schema and make sure all the proposed changes